PTO-1449 REPRODUCED

OIPE JC41 OCT 15 2002 PATENT & TRADEMARK OFFICE

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

October 9, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-006	09/756,398
APPLICANT	
Junming Le et al.	
FILING DATE	**GROUP**
January 8, 2001	1642

RECEIVED
OCT 17 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
KAC	AE2	5,360,716	11/01/94	Ohmoto, Y. et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
KAC	AM7	WO92/01059	01/23/92	PCT				
KAC	AN7	02-227095	09/10/90	JP			X	
KAC	AO7	61-047500	03/07/86	JP			X	

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

KAC	AT11	Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", *Hybridoma*, 19(6):463-471 (2000).
KAC	AU11	Paul, W.E. (Ed.), *Fundamental Immunology*, 3rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).
KAC	AV11	Borrebaeck, C.A.K. (Ed.), *Antibody Engineering*, 2nd Edition, Pub. Oxford University Press, p. 291 (1995).
KAC	AW11	Socher, S. *et al.*, "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", *Proc. Natl. Acad. Sci.*, USA 84:8829-8833 (1987).
KAC	AX11	Goh,C., "Tumour Necrosis Factors in Clinical Practice", *Annals of the Academy of Medicine*, 19(2):235-239 (1990).

EXAMINER	DATE CONSIDERED
Karen A. Canella	1/10/03